Which hormone is produced by the thyroid gland?

Choice A rationale

This response is incorrect because a persistent, dry cough in a patient on an ACE inhibitor is a significant adverse effect requiring medical evaluation. It is not something that will simply resolve on its own. The cough is thought to be caused by the accumulation of bradykinin and substance P in the lungs, which occurs due to the inhibition of the ACE enzyme, which normally degrades these peptides. This is a common but bothersome side effect that warrants a change in medication.

Choice B rationale

While increasing fluid intake is generally beneficial for health, it is not an effective treatment for a medication-induced cough. The cough is a direct result of the pharmacological action of the ACE inhibitor on the kinin-kallikrein system, not dehydration. The patient's cough is a physiological response to the medication, and fluids will not mitigate the underlying biochemical process causing the bradykinin accumulation and airway irritation.

Choice C rationale

This is the most appropriate action. The dry cough is a classic and common side effect of ACE inhibitors, affecting up to 20% of patients. It is caused by the accumulation of bradykinin, a vasodilator peptide, due to the inhibition of angiotensin-converting enzyme. This persistent and often irritating symptom may necessitate a change to an alternative class of antihypertensive drugs, such as an angiotensin II receptor blocker (ARB), which does not affect bradykinin levels.

Choice D rationale

Discontinuing the medication without consulting the healthcare provider is unsafe and outside the scope of nursing practice. Abruptly stopping an antihypertensive drug can lead to a dangerous rebound effect, causing a sudden and severe increase in blood pressure, known as a hypertensive crisis. The decision to change or stop a medication must always be made by the prescribing healthcare provider after evaluating the benefits versus the side effects.

Choice A rationale

Kava, despite being a natural product, is not safe for everyone. It has been associated with a significant risk of severe liver damage, including hepatitis, cirrhosis, and liver failure, even with moderate use. The active compounds, kavalactones, are metabolized by the liver and can cause hepatotoxicity, making it unsafe for individuals with pre-existing liver disease.

Choice B rationale

Kava is not a prescription medication in the United States or many other countries. It is widely available over-the-counter as a dietary supplement in various forms, such as capsules, powders, and teas. Its status as a supplement, rather than a drug, means it is not subject to the same strict regulations and oversight as prescription medications.

Choice C rationale

While some studies have explored kava's anxiolytic properties, it is not recommended for patients with depression. There is no strong evidence to support its use for this condition, and the potential for liver toxicity makes it a high-risk supplement. The risk of liver damage outweighs any potential benefit, especially given the availability of safer, effective antidepressant treatments.

Choice D rationale

The most appropriate response is to advise the patient to inform their healthcare provider. Kava can interact with many medications, particularly those metabolized by the liver, such as sedatives, anxiolytics, and antidepressants, increasing the risk of both drug toxicity and liver damage. A healthcare provider can assess for potential harmful interactions and advise on safe use.